All-round circulation: 17 million total circulation: 68 million

Issue price: 292.92 yuan P/E ratio: 17.76 times

Market value of circulation: 4.98 billion yuan annual performance: 1.38 yuan

Industry: biological region: Beijing

22. .89%

The net profit of the semi-annual report in 221 increased by 25.5% to 49.4% year-on-year

The company is a biotechnology company engaged in R&D, production, sales and technical services in biochemical reagent. Its main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as services such as the development of recombinant proteins and antibodies and biological analysis and detection. Customers include universities, scientific research institutes, pharmaceutical R&D enterprises and other domestic and foreign biological R&D units, including Tsinghua University, Peking University, Fudan University, University of Pennsylvania, Stanford University and other well-known universities at home and abroad, as well as large pharmaceutical R&D enterprises and biotechnology enterprises at home and abroad such as Wuxi PharmaTech and Sanofi.

most of the company's recombinant proteins are produced by HEK293 cells. The process flow chart is as follows:

From 218 to 22, the number of newly developed products of the company reached 4,979, 5,196 and 3,483 respectively. During the reporting period, the company's R&D strategy was appropriate to meet the research needs of downstream customers and meet the research hotspots of the industry, so the proportion of R&D products sold abroad showed an increasing trend year by year. In 22, the company responded quickly and developed Covid-19-related products, which met the market demand and was recognized by the market. The sales of related products were in good condition, and the number of newly developed products sold abroad reached 2,724, accounting for 78.21%.

The company's main business income is as follows

The company's financial position is as follows

According to the prospectus, from 218 to 22, Yiqiao Shenzhou's operating income was 139,227,7 yuan, 18,826,7 yuan and 1,596,293, yuan respectively, and the net profit attributable to shareholders of the parent company was 7. 9,14,8 yuan, 149,86, yuan and 1,298,643,5 yuan. In the past three years, the compound growth rate of revenue and net profit of the company reached 125.49% and 154.25% respectively. In 22, both revenue and net profit of the company increased explosively by more than seven times, of which the growth rate of net profit was significantly higher than that of operating income, and the gross profit rate of the company reached 968%. Yiqiao Shenzhou explained that since the COVID-19 epidemic, it has rapidly developed a series of biochemical reagent products such as Covid-19-related proteins and antibodies, which have been purchased in large quantities by domestic and foreign customers, and the company's operating performance has increased rapidly. In 22, the company's Covid-19 related products revenue reached 1.342 billion yuan, accounting for 84.7% of the current operating income.

It is worth noting that although the epidemic is sporadic, and the company also suggested in the prospectus that the COVID-19 epidemic may be gradually controlled, and the income of related products may fall back, but unlike most enterprises in the industry that have affected part of their main business income due to the explosive growth of COVID-19 epidemic, Yiqiao Shenzhou has increased due to the scale effect brought by the expansion of production and sales of the company and the income of service types with higher gross profit margin in CRO services. After excluding Covid-19-related products, the company's non-COVID-19 epidemic operating income in 22 reached 254,218,5 yuan, with a year-on-year growth rate of 4.59%, and the gross profit margin increased by 5.96 percentage points to 89.95%.

The purpose of the raised funds is as follows

Personal summary of benchmarking companies in the same industry

The company is a biotechnology company engaged in R&D, production, sales and technical services in biochemical reagent, and its main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as services such as development of recombinant proteins and antibodies and biological analysis and detection. Last year, the outbreak of the epidemic led to a big outbreak of the company's performance, and the first share was issued at a high price on the Growth Enterprise Market, which doomed that the stock would not be dull. The winners were already imagining that the price exceeded Maotai, and some were not optimistic. Some thought that the stock would be broken within six months. Both sides were arguing with each other and had a good time. This is the fun of stock trading. Different positions will definitely lead to different conclusions. Now the media is too developed, and Yiqiao Shenzhou is distributed on the whole network, and the chips are in the hands of retail investors. The retail investors who win the lottery are counting on this stock to turn over and buy a house and a car, so the first hidden danger will arise tomorrow. The low-winning bidder who opened the market is unwilling to sell the turnover rate, and who will take over the offer if it reaches the goal of the winning bidder? In addition, the company's performance continues to develop. The soaring performance of the company last year was mainly affected by the COVID-19 epidemic. It is estimated that this performance will be the highest point of the company in recent years. This is the so-called debut is the peak. In 221, the company's overall operating income and profit level are at risk of falling by more than 5% compared with the previous year, and its performance growth is not sustainable. This is the second hidden danger. Third, judging from the previous high-priced stock issuance, A-share * * * issued 31 high-priced stocks with an issue price higher than that of 1 yuan, among which the pharmaceutical and biotechnology industries have the largest number, with six, and Yiqiao Shenzhou is just in this industry. Judging from the trend of the first day of previous issuance, the 2 high-priced stocks listed after 21 all rose on the first day, and the rice technology listed in March this year rose by 296.33% on the first day. However, there are 1 with an increase of less than 5%, accounting for 5%. Among them, the Youan design with the smallest increase on the first day is only 7.67%, which shows a huge difference. Therefore, it is inevitable that Yiqiao Shenzhou, the highest issue price in history, will rise, but it is difficult to estimate the expected goal of rising to the winner. In combination with the above, I'm going to the theatre tomorrow, and I won't take part in the battle unless I have a chance to take part in it.